Mobile

An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosis

Mise à jour : Il y a 4 ans
Référence : EUCTR2007-006648-23

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the efficacy of omalizumab (Xolair) in adolescent and adult patients with cystic fibrosis (CF) complicated by acute or chronic allergic bronchopulmonary aspergillosis (ABPA) •as measured by the proportion of patients requiring rescue with corticosteroids following 6 months of study treatment •as measured by time to deviation from the protocol prescribed steroid tapering regime

Critère d'inclusion

  • Patients with cystic fibrosis complicated by allergic bronchopulmonary aspergillosis

Liens